THE DEAL, AT A GLANCE
From the announcementAddex spin-out Neurosterix
01What it does“The closing of this significant financing is a huge endorsement of the allosteric approach pioneered by Addex in schizophrenia as well as other neuropsychiatric…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Addex TherapeuticsFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedAddex spin-out Neurosterix raised $105M Series B, announced 2026-11-12From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersAddex spin-out Neurosterix raised a $105M Series B, a round at the 78th percentile by size among tracked Unclassified rounds.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Addex spin-out Neurosterix · Financing Record
Explore source-linked visual explanations for Addex spin-out Neurosterix. Unsupported claims are withheld while source review continues.
Record 15852 · Recorded date: 2026-11-12
What it does
Building on decades of innovation in allosteric neuroscience, Neurosterix is redefining what’s possible.
Source: neurosterix.com ↗